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PAK4 suppresses RELB to prevent senescence-like
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Overcoming cellular growth restriction, including the evasion of cellular senescence, is a
hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer sub-
types and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression
promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT
driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer
cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4
overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-
induced senescence. Mechanistically, a PAK4 – RELB - C/EBPβ axis controls the senescence-
like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA
interaction, transcriptional activity and expression of the senescence regulator C/EBPβ.
These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-
induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition.
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Breast cancer is the most common malignancy in womenand causes significant lethality1. It is therefore imperative tofind molecular actors that may be exploited as therapeutic
targets.
Cellular senescence is a stress-inducible fail-safe mechanism
that complements apoptosis in preventing the proliferation of
damaged cells, while also contributing to ageing2. The senescent
phenotype is highly heterogeneous and can be induced by dif-
ferent stimuli, including by oncogenes in untransformed cells
(oncogene-induced senescence, OIS)3. Importantly, the identifi-
cation of senescent cells in several pre-malignant or benign
conditions suggests that senescence potently prevents cancer by
acting as a major barrier to cancer development4. While no
universal senescence-specific markers exist5, senescent cells are
characterized by a durable proliferative arrest often accompanied
by increased senescence-associated β-galactosidase (SA-β-gal)
activity and a senescence-associated secretory phenotype (SASP)5
consisting of a plethora of secreted molecules that influence
senescence through complex and poorly understood autocrine
and paracrine means.
The nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) acts a master regulator of the SASP6. NF-κB sig-
naling is categorized into canonical (or classical) and non-
canonical (or alternative) pathways, based on which components
engage in the signaling cascade7. Canonical NF-κB signaling
entails the processing of the precursor form NF-κB1 into the
active form p50 and nuclear accumulation of RELA-p50 dimers.
Distinctly, noncanonical NF-κB signaling involves the processing
of NF-κB2 into p52 and assembly of RELB-p52 complexes7.
While canonical NF-κB signaling (explicitly RELA) as well as
CCAAT/enhancer-binding protein beta (C/EBPβ) are key tran-
scriptional SASP regulators8 and thereby firmly linked to cellular
senescence, the potential involvement of noncanonical NF-κB
signaling in senescence has remained largely unknown.
The serine/threonine p21-activated kinases (PAKs) are recog-
nized for their privileged position at the intersection of major sig-
naling pathways required for oncogenesis9. Among PAKs, PAK4
plays a pivotal role in various cancer-associated cellular events9,
which includes regulating different aspects of proliferation. In
agreement, PAK4 is frequently overexpressed in cancer and corre-
lates to poor patient prognosis in several cancer forms10. Yet, the
potential functional role of PAK4 during cancer development
in vivo has remained unknown and our understanding of the
PAK4 signaling pathways that affect tumorigenesis is so far sparse.
Here we show that PAK4 is overexpressed in breast cancer
associated with poor prognosis. PAK4 overexpression abrogates
OIS in untransformed human mammary epithelial cells
(HMECs), leads to mammary tumors in mice and suppresses
senescence-like growth arrest in various breast cancer models,
controlled by a PAK4–RELB–C/EBPβ regulatory axis. Our results
reveal a critical function of PAK4 in breast cancer pathogenesis
and identify a druggable vulnerability that may be exploited for
breast cancer therapy.
Results
PAK4 expression is linked to breast cancer patient outcome.
The PAK4 gene is located at a chromosomal region (19q13.2)
frequently amplified in breast cancer with basal-like features11
and consistently, PAK4 was found overexpressed in a small set of
human breast cancer specimens12. In addition, we reported that
high PAK4 levels correlate with poor survival of endocrine-
treated breast cancer patients13. However, expression levels and
copy number variation of PAK4 in relation to breast cancer
patient outcome has not yet been examined in more general and
larger sets of breast cancer patients. To this end, we analyzed the
METABRIC14 dataset and found that PAK4 transcript expression
was approximately twofold higher in breast tumors compared
with their normal counterparts (Fig. 1a and Supplementary
Fig. 1a). PAK4 mRNA levels were high across all breast cancer
subtypes both when using the PAM50 signature15 (Fig. 1b) and
the IC10 classification14 (Fig. 1c). The PAK4 overexpression in
breast cancer relative to normal breast tissues was confirmed in
two independent breast cancer datasets16,17 (Supplementary
Fig. 1b, c). PAK4 protein levels displayed a similar trend within a
panel of six human breast cancer cell lines (Supplementary
Table 1), most exhibiting PAK4 overexpression as compared with
two independent batches of primary, non-immortalized HMECs
(Supplementary Fig. 1d).
To analyze the clinical outcome of breast cancer patients in the
METABRIC cohort, patients were stratified according to quartiles
of PAK4 expression. Higher PAK4 expression was associated with
worse disease-specific survival (DSS) in the entire cohort (Fig. 1d)
as well as in patients that did not receive systemic adjuvant
treatment (Fig. 1e). High expression levels of PAK4 also
correlated with poor overall survival (OS) (Supplementary
Fig. 1e). These conclusions withstand multivariate analyses,
including lymph node status, breast cancer subtype, tumor size,
and grade (Supplementary Tables 2 and 3).
PAKs overexpression in cancer varies widely and may be due
to both mRNA upregulation and/or gene amplification10. PAK1
is the most amplified PAK in breast cancer (~8%), while
PAK4 amplification is only detected in ~2% of breast tumors in
The Cancer Genome Atlas (TCGA) cohort10. Using cBioPortal18,
we replicated this finding and also expanded the analysis to the
METABRIC dataset, where we found a comparable fraction of
tumors with PAK4 amplification (Supplementary Table 4).
Interestingly, patients carrying tumors with PAK4 amplification
tended to exhibit worse prognosis (Supplementary Fig. 1f, g). We
also analyzed PAK4 copy number and mutational status in the
breast cancer cell lines used throughout the study, but no relevant
alterations were found (Supplementary Table 1).
Together, this indicates that PAK4 overexpression in breast
cancer correlates with unfavorable disease outcome.
PAK4 overexpression promotes mammary tumors. While
grafted immortalized mouse mammary epithelial cells over-
expressing PAK419 and breast cancer cells with PAK4 depletion20
shed some light on the potential relevance of PAK4 in breast
cancer growth in vivo, the role of PAK4 during cancer develop-
ment has not yet been examined.
To this end, transgenic MMTV–PAK4-overexpressing mice
were generated in an inbred FVB/N strain (Supplementary
Fig. 2a, b). Young MMTV–PAK4 mice were healthy, fertile, and
had no overt phenotypic differences from wild-type (wt) mice.
Importantly, from 6 months of age, PAK4-overexpressing virgin
and nulliparous females exhibited lesions that eventually devel-
oped into mammary tumors in 25% of the cases (Fig. 2a, b).
MMTV–PAK4 tumors morphologically resembled invasive
lobular breast cancer and exhibited cribriform and fibrotic
morphologies (Supplementary Fig. 2c). We also extracted
genomic DNA from three mammary tumors that arose in virgin
MMTV–PAK4 female mice (20–24 months old) plus liver tissue
to conduct whole-exome sequencing (WES). The Pak4 construct
was visible in the sequencing coverage profiles as evident by very
distinct exon/intron boundaries (Supplementary Data 1). Cover-
age for Pak4 was about ten times higher than for genes
surrounding the Pak4 locus suggesting multiple integration sites.
Interestingly, activating Kras mutations, including G12C and
G13D, were found in two out of three MMTV–PAK4 tumors
(Supplementary Data 1).
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PAK4 depletion impairs PyMT-driven mammary tumorigen-
esis. To further assess the function of PAK4 during mammary
cancer development, we generated an additional genetically
engineered mouse based on the widely used and relevant Polyoma
Middle T (PyMT) transgenic breast cancer mouse model that is in
part driven by PyMT-induced RAS signaling21,22. In this model,
PyMT oncoprotein expression in the mammary epithelium is
driven by the mouse mammary tumor virus (MMTV) pro-
moter21. After a short latency, PyMT mice stochastically develop
focal mammary tumors expressing biological markers consistent
with those expressed in human breast cancers and that recreate
stages similar to human breast cancer progression22. Importantly,
PAK4 protein levels were elevated in PyMT-driven mammary
tumors as compared with paired adjacent mammary tissues
(Supplementary Fig. 2d–f). However, MMTV–PyMT tumors do
not exhibit PAK4 amplification23.
We crossed PAK4fl/fl mice24 with MMTV-Cre mice/line D25 to
generate mice carrying conditional PAK4 depletion in the
mammary epithelium (MMTV-Cre;PAK4fl/fl, hereafter referred
to as PAK4MEp−/− for simplicity). No significant defects in
mammary gland morphogenesis were apparent in PAK4MEp−/−
mice26. PAK4fl/fl mice were then interbred with MMTV-Cre and
MMTV–PyMT mice to generate MMTV–PyMT;MMTV-Cre;
PAK4fl/fl (PyMT;PAK4MEp−/−) and MMTV–PyMT;MMTV-Cre
(PyMT;PAK4MEp+/+) control mice (Fig. 2c). PyMT-driven
mammary tumorigenesis was examined in virgin females in the
presence or absence of endogenous PAK4.
By 12 weeks of age, the PyMT oncogene induced extensive
hyperplasia and mammary intraepithelial neoplasia in PyMT;
PAK4MEp+/+ control animals. In contrast, PyMT;PAK4MEp−/−
glands were only mildly hyperplasic and exhibited fewer and
smaller foci intermingled with normal ductal structures (Fig. 2d–e
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Fig. 1 PAK4 overexpression in breast cancer is associated with unfavorable outcome. a PAK4 mRNA expression in breast carcinomas (n= 1992) and
normal breast tissues (n= 144) in the METABRIC breast cancer cohort. b PAK4 expression across the five distinct molecular subtypes of breast cancer
based on the PAM50 signature in the METABRIC breast cancer cohort (BL: Basal-like n= 331; H2: HER2-enriched n= 240; LA: Luminal A n= 721; LB:
Luminal B n= 492; NBL: Normal Breast-like n= 202). c PAK4 expression among the ten distinct integrative clusters (IC) of breast cancer using the IC10
classification in the METABRIC breast cancer cohort (IC1 n= 76; IC2 n= 45; IC3 n= 156; IC4 n= 167; IC5 n= 94; IC6 n= 44; IC7 n= 109; IC8 n= 143;
IC9 n= 67; IC10 n= 96). d Kaplan–Meier plot and analysis of disease-specific survival (DSS) in the METABRIC breast cancer cohort stratified according to
quartiles of PAK4 expression. e Kaplan–Meier plot and analysis of DSS in the METABRIC cohort without systemic adjuvant treatment stratified according
to quartiles of PAK4 expression. In a–c data are represented as boxplots where the middle line is the median, the lower and upper hinges correspond to the
first and third quartiles, the upper whisker extends from the hinge to the largest value no further than 1.5 × IQR from the hinge (where IQR is the inter-
quartile range) and the lower whisker extends from the hinge to the smallest value at most 1.5 × IQR of the hinge, while data beyond the end of the
whiskers are outlying points that are plotted individually. The Fold Change and the p-value of a Mann–Whitney test are indicated in a. PAK4 expression in
normal breast tissues (N) as seen in a is displayed to facilitate comparisons in b and c. The Hazard Ratios (HR), 95% confidence intervals (CI) and p-values
by the log-rank (Mantel–Cox) test are indicated in d and e. n is specified for each patient subgroup below d and e
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and Supplementary Fig. 2g). Consistently, PyMT;PAK4MEp−/−
female mice developed palpable tumors significantly later than
PyMT;PAK4MEp+/+ mice, with the median tumor onset delayed
on average by 22 days (Fig. 2f). This delay in tumor onset was also
reflected in the median animal survival (Fig. 2g).
MMTV–PyMT also drives mammary tumor development in
male mice, providing a different mammary tumor model with a
considerably longer latency than in females. Strikingly, the effects
of PAK4 gene depletion on tumor formation were even more
prominent in the male PyMT (Fig. 2h).
Given the inherent caveats of the mouse strains herein
employed25, we evaluated the extent of PAK4 depletion in late
stage mammary tumors that arose in females of both genotypes
by measuring PAK4 protein levels by different techniques. While
there was an overall consistent decrease in the levels of PAK4 in
PyMT;PAK4MEp−/− tumors compared with controls, there was
still substantial PAK4 expression in some PyMT;PAK4MEp−/−
tumors, with significant variation between animals detected by
immunoblot (Supplementary Fig. 2h, i). To analyze the spatial
distribution of remaining PAK4 expression in the tumors, we
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Fig. 2 PAK4 promotes murine mammary tumorigenesis. a Representative images of mammary epithelium from 6-month-old females of the indicated
genotypes. Scale bars, 200 μm. b Tumor incidence in aged virgin mice (20–24 months old) of the indicated genotypes (n= 16 wt FVB and n= 20
MMTV–PAK4). c Schematic diagram of the MMTV–PyMT mouse strains used. d Representative images of carmine-stained wholemounts of inguinal
mammary glands from 12 weeks old female mice of the indicated genotypes. Scale bar, 5 mm. White asterisks denote lymph nodes. e Quantification of
carmine-filled fat pad area (n= 6 per indicated genotype). f Kaplan–Meier plot of tumor-free survival in female mice of the indicated genotypes (n= 14
PyMT;PAK4MEp+/+ and n= 6 PyMT;PAK4MEp−/−). g Kaplan–Meier plot of overall survival in female mice of the indicated genotypes (n= 18 PyMT;
PAK4MEp+/+ and n= 6 PyMT;PAK4MEp−/−). h Kaplan–Meier plot of tumor-free survival in male mice of the indicated genotypes (n= 9 PyMT;
PAK4MEp+/+ and n= 10 PyMT;PAK4MEp−/−). Data are represented as percentage in b and as mean ± SEM in e. The p-values by chi-square test in b and
by two-tailed unpaired t test in e are indicated. Dots in e depict individual samples. The Hazard Ratios (HR) and p-values by log-rank (Mantel–Cox) test are
indicated in f–h
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detected PAK4 mRNA levels using in situ hybridization (ISH/
RNAScope). We found an overall lower PAK4 expression in early
lesions compared with late-stage PyMT-driven tumors; that
PAK4 expression is consistently less in the tissues harvested from
PyMT;PAK4MEp−/− mice as compared with control; that residual
PAK4 expression occurred specifically in tumor areas of PyMT;
PAK4MEp−/− tissues (Supplementary Fig. 2j, k). This indicates
that PAK4 was not completely depleted from the mammary
tissues of PyMT;PAK4MEp−/− mice and PAK4 may therefore still
contribute to tumorigenesis. ISH analysis of control tissues also
points to the existence of small sub-populations of PyMT cells
that express low or no PAK4. The behavior of such cells is likely
not affected by Cre-mediated PAK4 depletion and hence, these
cells may contribute as well to the tumor masses. In addition, we
performed immunohistochemistry (IHC) with an anti-PAK4
antibody that we generated for this purpose (pab #73). The IHC
results were in agreement with the other techniques (IB and ISH)
used to evaluate PAK4 expression in these murine tissues
(Supplementary Fig. 2l, m). The PAK4 labeling score correlated
negatively with the mouse survival time (Supplementary Fig. 2n).
While several aspects might contribute to the variation of
PAK4 expression observed, the most likely explanation stems
from the previously recognized stochastic nature of transgene
expression, including MMTV-Cre25. In our model, the expression
of Cre recombinase and PyMT is not coupled within the exact
same mammary epithelial cells, meaning that, stochastically, a
mosaic pattern of transgene expression is expected, where some
cells will co-express Cre and PyMT and other cells will only
express Cre, PyMT, or none of the transgenes25. Due to the
strong nature of the PyMT oncogene, it is likely that cells where
only PyMT is expressed may eventually contribute to subpopula-
tions of tumor cells, where PAK4 is not subjected to Cre-
mediated knockout. To address this complexity, we have included
IHC for Cre in tumors that arose in mice of both genotypes and
scored the Cre expression (Supplementary Fig. 2o, p). A mosaic
pattern of Cre expression was indeed present, particularly in PyMT;
PAK4MEp−/− mice. A mosaic pattern of PyMT expression is less
relevant here because only PyMT-transformed cells would develop
into tumors. Interestingly, we observed a selectivity against Cre-
positive cells in tumors that arose in PyMT;PAK4MEp−/− mice
(Supplementary Fig. 2o, p), which likely underscores the here
observed role of PAK4 in tumor development. This heterogeneity
makes it challenging to relate PAK4 expression to other
molecular events in this model. Nevertheless, our mouse model
provides compelling evidence that mammary epithelial disruption
of PAK4 results in impaired PyMT-induced tumorigenesis.
PAK4 depletion induces senescence-like growth arrest. To gain
better understanding of the role of PAK4 in breast cancer, we
performed RNA-Sequencing (RNA-Seq) of two human breast
cancer cell lines, Hs 578T and BT-549, 72 h after transfection with
PAK4-targeting siRNA. All replicates aligned well with >75%
total mapping rate and a high level of concordance with paired
reads (Supplementary Data 2). We observed a total of 500 versus
1151 genes that were differentially expressed (DE) following
PAK4 knockdown in Hs 578T versus BT-549 cells, with 319
versus 702 genes downregulated and 181 versus 449 genes
upregulated (p < 0.05 by Wald test with Benjamini–Hochberg
false discovery rate correction and fold change ≥ 1.5) (Supple-
mentary Fig. 3a, b and Supplementary Data 3 and 4). Impor-
tantly, PAK4 was significantly downregulated in both datasets
(Supplementary Fig. 3a, b).
Ingenuity Pathway Analyses27 reports were similar for both cell
lines, revealing an overall prevalence of categories related to cell
survival, growth, proliferation, and movement among the top
altered molecular and cellular functions upon PAK4 knockdown
(Supplementary Fig. 3c, d).
Guided by the selectivity against Cre-positive cells observed in
the tumors that arose in PyMT;PAK4MEp−/− mice; the Ingenuity
Pathway Analyses upon PAK4 knockdown described above and
an observation in glioblastoma28, we analyzed potential
senescence-like features in breast cancer cells upon PAK4
depletion. After transient transfection of two independent small
interfering RNAs (siRNAs) targeting the human PAK4 gene, Hs
578T breast cancer cells adopted a flatter and larger senescence-
associated morphology and exhibited elevated SA-β-gal activity
(as measured with the two substrates X-Gal29 and MUG30) that
was accompanied by a significant decrease in BrdU-incorporation
(Fig. 3a–d). Genes involved in cell cycle arrest, DNA damage/
repair, and SASP factors are typically upregulated in senescent
cells. Several of such genes were also upregulated upon PAK4
depletion in the RNA-Seq datasets and we validated a selection of
these by RT-qPCR in independent RNA preparations of Hs
578T cells (Supplementary Fig. 3e). PAK4 knockdown also
increased protein expression of the known senescence-regulators
p53 and p21 (Supplementary Fig. 3f).
We next examined if PAK4 depletion induced senescence
hallmarks in a diverse collection of cancer cells using several
in vitro, in vivo, and ex vivo models. PAK4 was firstly abrogated in
an extended panel of breast cancer cell lines BT-549, MDA-MB-
231, MCF7, and T-47D (Supplementary Table 1). Increased SA-β-
gal activity and decreased cell proliferation, both typical senescence
responses, were observed upon PAK4 knockdown in all breast
cancer cell lines here tested (Fig. 3f and Supplementary Fig. 3g, h).
However, PAK4 knockdown in two independent batches of non-
immortalized HMECs (#1 and #2) that express low levels of PAK4
(Supplementary Fig. 1d) did not induce SA-β-gal (Fig. 3f and
Supplementary Fig. 3g). A primary cell line derived from a PyMT-
driven tumor31 also exhibited increased SA-β-gal activity when
transfected with two independent siRNAs targeting murine PAK4
(Supplementary Fig. 3i). In addition, in contrast to untransformed
HMECs, ex vivo bulk tumor cells derived from breast cancer
patients (patient-derived cells, PDCs) arrested proliferation upon
PAK4–siRNA treatment (Supplementary Fig. 3j). Expression of an
siRNA-resistant PAK4 mutant restored the proliferation of breast
cancer cells (Supplementary Fig. 3k), while the proliferation of
breast cancer cells highly expressing kinase-dead
EGFP–PAK4–M350 was impaired to an extent similar to that of
siPAK4-transfected cells (Supplementary Fig. 3l). This suggests that
PAK4-M350 acts as a dominant negative with respect to the studied
phenotype. Moreover, breast cancer cells were generated using
CRISPR/Cas9 genome editing with single guide RNAs (sgRNAs)
targeting PAK4. The growth of sgPAK4 cells was dramatically
inhibited as compared with parental cells, accompanied by
increased SA-β-gal activity (Fig. 3g–j), consistent with the effect
of siRNA-mediated PAK4 knockdown. Different PAK4-depleted
breast cancer cell lines exhibited arrest in the G0/G1 or G2/M
phases of the cell cycle (Supplementary Fig. 3m–o), as previously
reported for cancer cells undergoing senescence2.
Finally, we examined malignant cells of more diverse
histological origins. PAK4 is overexpressed in pancreatic
adenocarcinoma10. Consistently, PAK4 siRNA induced SA-β-gal
in three out of four tested human pancreatic adenocarcinoma cell
lines as well as in cells derived from the KPC transgenic mouse
model of pancreatic adenocarcinoma32 (Supplementary Fig. 3p,
q). Given PAK4 overexpression in ovarian tumors10, we also
analyzed ovarian cancer cells and found that PAK4 knockdown
induced SA-β-gal in OVCAR-3 cells, but not in TOV-21G or
Caov-3 cells (Supplementary Fig. 3r). Thus, eleven out of fourteen
cancer cell lines here examined exhibited increased SA-β-gal
activity upon PAK4 knockdown.
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Taken together, this shows that inhibition of PAK4 triggers a
senescence-like response in cancer cells of different histological
origins.
PAK4 overexpression overcomes H-RAS-V12-induced senes-
cence. Considering also that MMTV–PAK4 overexpression may
have facilitated KRAS-driven mammary tumors (Fig. 2b and
Supplementary Data 1), and that oncogenic RAS-signaling in
untransformed cells activates OIS3, we tested the hypothesis that
PAK4 may overcome oncogenic RAS-induced senescence. We
utilized an established model where inducible H-RAS-V12 causes
senescence-linked growth arrest in untransformed HMECs33.
Indeed, while induction of H-RAS-V12 in this model induced an
almost complete proliferation block, consistent with previous
results from this model33, overexpression of EGFP–PAK4
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partially rescued proliferation (Fig. 3k). This suggests that PAK4
overexpression may overcome the OIS barrier to cancer.
PAK4 inhibition induces senescence-like programs in vivo. We
then expanded our analyses to three distinct in vivo models. First,
we analyzed X-Gal-stained mammary tissues from our model of
PyMT-driven tumorigenesis with conditional PAK4 knockout
(Fig. 2 and Supplementary Fig. 2) harvested at 8–11 weeks of age.
This time point was selected because senescent cells are abundant
in the preneoplastic stage of certain cancers4. While most lesions
displayed X-Gal positivity, we found an increase, albeit modest, in
X-Gal positivity in PyMT;PAK4MEp−/− lesions as compared with
control PyMT mice (Fig. 4a–c).
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Next, we treated MMTV–PyMT mice with the PAK4 inhibitor
PF-0375830934. Because PF-03758309 has been previously shown
to block the growth of multiple human tumor xenografts34, we
used acute treatment where PF-03758309 was injected intratu-
morally for 5 days (Fig. 4d) followed by X-Gal staining. PF-
03758309-treatment resulted in a higher proportion of X-Gal-
covered tumor areas compared with vehicle-treated samples
(Fig. 4e, f).
To further test the in vivo function of PAK4, MCF7 cells stably
expressing shPAK4 or shControl (Supplementary Fig. 4a) were
xenografted onto the back of nude mice. After injection and once
the tumors were palpable (9 days post injection), we followed the
detailed kinetics of tumor growth in vivo (Fig. 4g, h). shPAK4
tumors grew slower and were smaller at the experimental
endpoint than control tumors (Fig. 4h, i and Supplementary
Fig. 4b). Importantly, tumors expressing shPAK4 exhibited
several hallmarks of senescence, including abundant SA-β-gal
activity, decreased Ki67 positivity, and accumulated p53 (Fig. 4j
and Supplementary Fig. 4c–e).
By performing analyses of gene expression data across the
METABRIC cohort, we also found that higher expression of
PAK4 was strongly correlated with known modules that reflect
biological processes in breast cancer35,36 (Supplementary Fig. 4f).
Of relevance, we observed a positive correlation between PAK4
expression and the breast cancer proliferation score (Fig. 4k).
Together, these experiments extend our findings on the role of
PAK4 to in vivo and patient settings.
PAK4 inhibits NF-κB signaling. To probe into the mechanism of
PAK4 regulation of senescence-like growth arrest, we explored our
RNA-Seq data of genes DE upon PAK4 knockdown. Interestingly,
from both Hs 578T and BT-549 datasets we identified enrichment
in NF-κB signatures, a crucial transcriptional regulator of the
senescent phenotype6, with a large number of NF-κB (RELA)
target genes DE upon PAK4 knockdown (Fig. 5a and Supple-
mentary Fig. 5a and Supplementary Data 5 and 6). Upregulation
of several NF-κB target genes upon PAK4 knockdown was vali-
dated by RT-qPCR in Hs 578T cells, including the NF-κB subunits
NFKB1, NFKB2, and RELB as well as the previously characterized
NF-κB response genes CD82, S100A4, TIMP2, CDKN1C, PRKCD,
TWIST1, SPP1, TP53, and TRAF2 (Fig. 5b).
Importantly, we found that a metagene signature of NF-κB
signaling37 negatively correlated with PAK4 expression in the
METABRIC breast cancer patient dataset, thus extending our
findings into patient settings (Fig. 5c). Interestingly, this
correlation was only apparent in breast tumors but not in normal
breast tissue.
PAK4 regulates senescence-like growth arrest via RELB. To
further investigate a potential relationship between PAK4 and
NF-κB subunits in breast cancer, we performed correlation ana-
lyses for the expression of PAK4 and all NF-κB subunits in the
METABRIC dataset. Considering expression as continuous vari-
ables, the expression of PAK4 and RELB displayed the strongest
significant inverse association (Fig. 5d and Supplementary
Fig. 5b). This inverse correlation was also observed at the protein
level in Hs 578T breast cancer cells where PAK4 knockdown
upregulated RELB (Supplementary Fig. 5c). In support of a
potential clinical relevance, we also found that low PAK4/high
RELB expression was associated with better prognosis in the
HER2-positive breast cancer subtype (Supplementary Fig. 5d, e),
in which PAK4 expression was the highest (Fig. 1b).
We then examined if the induction of growth arrest upon
PAK4 knockdown in cancer cells functionally involved RELB.
Indeed, RELB co-depletion with PAK4 restored the proliferative
capacity of Hs 578T cells, defining RELB as essential for growth
arrest upon PAK4 depletion (Fig. 5e and Supplementary Fig. 5c).
Thus, PAK4 is a negative regulator of NF-κB signaling in breast
cancer cells, regulating senescence-like growth arrest via the
noncanonical NF-κB subunit RELB.
RELB-Ser151 phosphorylation promotes cell proliferation.
FLAG-tagged as well as endogenous PAK4 immunoprecipitated
endogenous RELB, while FLAG-tagged RELB immunoprecipi-
tated endogenous PAK4 (Fig. 6a and Supplementary Fig. 6a–c).
Interestingly, PAK4 strongly phosphorylated the REL-
homology domain of RELB (RELB–RHD) (Fig. 6b, c and
Supplementary Fig. 6d, e), consistent with NF-κB activity being
controlled by phosphorylation7. Mapping Mass Spectrometry
(MS) analysis identified serine 151 (Ser151) as a putative
PAK4 site within RELB–RHD (Supplementary Fig. 6f). Phosphor-
ylation of RELB–Ser151 is also indicated in the Phosida38 database
(Supplementary Fig. 6g). Importantly, phospho-null RHD-S151A
(Ser→Ala substitution) abolished the PAK4 phosphorylation of
the RHD, validating the MS results (Fig. 6c). Sequence alignment
showed conservation of RELB–Ser151 across species (Fig. 6d).
In line with the notion that RELB signaling promotes growth
arrest, overexpression of FLAG-tagged RELB wt led to reduced
EdU incorporation in Hs 578T breast cancer cells, while
expression of a FLAG-tagged phospho-mimicking RELB–S151E
(Ser→Glu substitution) did not affect proliferation (Fig. 6e, f).
These results indicate that PAK4 is a RELB-kinase and that
RELB phosphorylation on Ser151 is a novel mechanism
controlling cell proliferation.
RELB–Ser151 governs its DNA-binding and C/EBPβ tran-
scription. Interestingly, in the RELB–DNA complex crystal
structure39, Ser151 forms a hydrogen bond with the DNA
backbone that, according to our computational modeling is
abolished by Ser151 phosphorylation, thereby potentially weak-
ening DNA binding (Fig. 7a). Importantly, this prediction was
supported by our experiments, since the phospho-mimetic
RELB–S151E had defective DNA binding in vitro as compared
with wt RELB and the phospho-null RELB–S151A (Fig. 7b, c).
Fig. 4 PAK4 inhibition induces senescence-like programs in vivo. a Schematic diagram of the experimental set up using the transgenic mouse model.
b Representative X-Gal-stained PyMT-driven early mammary lesions from each indicated genotype. Scale bar, 100 μm. c Quantification of the percentage
of X-Gal+ cells per lesion (PyMT;PAK4MEp+/+ n= 90 and PyMT;PAK4MEp−/− n= 75, entailing 15 lesions per animal derived from 5 to 6 animals per
group). d Schematic diagram of the experimental set up using the PAK4 inhibitor PF-03758309. e Representative images of X-Gal-stained sections of
PyMT tumors that were treated with the PAK4 inhibitor (PF-03758309) or DMSO. Scale bar, 250 μm. f Quantification of X-Gal+ areas in tumor sections of
PyMT-treated tumors (DMSO n= 5 and PF-03758309 n= 8). g Schematic diagram of the experimental set up using xenografted MCF7 cells. h Kinetics of
tumor growth for MCF7 cells stably expressing shPAK4 or shControl injected subcutaneously onto the back of nude mice (shControl n= 8 and shPAK4
n= 10). i Quantification of tumor weight at the experimental endpoint (shControl n= 8 and shPAK4 n= 10). j Representative X-Gal-stained wholemount
tumor slices of the indicated groups. k Correlation between PAK4 expression and the proliferation score of breast tumors in the METABRIC breast cancer
cohort (n= 1992). Data are represented as mean ± SEM in c, f, h, and i. p-values by two-tailed unpaired t test are indicated in c, f, and i and by two-way
ANOVA (repeated measurements) followed by Bonferroni's multiple comparisons post hoc test in h. The Spearman correlation and p-value by Spearman’s
test are indicated in k. The colored dots represent the PAM50 subtypes as displayed in Fig. 1b
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Fig. 5 PAK4 inhibits senescence-like growth arrest via the NF-κB subunit RELB. a Column clustered heatmaps of NF-κB (RELA) target genes that are
differentially expressed in Hs 578T cells upon siPAK4. Genes are by column and samples by row. The color intensity represents column Z‐score, where red
indicates highly and blue lowly expressed. Selected NF-κB target genes are indicated. b RT-qPCR validation of differentially expressed NF-κB target genes in
Hs 578T cells. mRNA was prepared 72 h after transfection with the indicated siRNAs (n= 3 per group). c Correlation between PAK4 expression and an
NF-κB signature in breast tumors (T) and normal tissue (N) in the METABRIC dataset. d Correlation between the expression of PAK4 and the alternative
NF-κB subunit RELB in breast tumors (T) and normal tissue (N) in the METABRIC dataset. e Quantification of EdU+ cells in Hs 578T cells 4 days after
transfection with the indicated siRNAs (n= 3 per group). Data are represented as mean ± SEM in b and e. p-values by two-tailed unpaired t test are
indicated in b and by one-way ANOVA followed by Tukey's post hoc test in e. The Spearman correlations and p-values by Spearman’s test are indicated in
c and d for tumors (T, blue, n= 1992) and normal tissue (N, gray, n= 144)
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Consistently, PAK4 overexpression in breast cancer cells
inhibited RELB binding to DNA, while PAK4 depletion increased
RELB DNA-binding (Fig. 7d, e and Supplementary Fig. 7a, b). To
examine Ser151-phosphorylation effects on RELB transcriptional
activity, we overexpressed FLAG-tagged RELB wt and
RELB–S151E and compared, by qPCR array, the expression of
candidate genes from our lists of DE genes upon PAK4
knockdown derived by RNA-Seq (Supplementary Fig. 7c and
Supplementary Data 3 and 4). Interestingly, C/EBPβ, an
important senescence regulator8, emerged as the top altered
candidate (Fig. 7f and Supplementary Fig. 7c). In agreement, we
found a positive correlation between RELB and C/EBPβ
expression in the METABRIC patient dataset (Fig. 7g). Further,
PAK4 silencing increased C/EBPβ expression (Fig. 7h) and co-
depletion of C/EBPβ with PAK4 partially rescued the inhibited
proliferation induced by PAK4 knockdown (Fig. 7i and
Supplementary Fig. 7d).
These data demonstrate that phosphorylation of Ser151
abrogates RELBDNA-binding and consequently negatively influ-
ences RELB-mediated transcription (i.e., C/EBPβ expression)
impacting cell proliferation (Fig. 7j).
Discussion
Here we identify PAK4 as an attractive breast cancer drug target
candidate given its overexpression in breast cancer patients
negatively affecting prognosis and its key function in evading
senescence-like growth arrest in breast cancer cells via the non-
canonical NF-κB component RELB.
The lack of investigations on the potential role of PAK4 in
tumorigenesis in vivo prompted us to establish two transgenic
models, with PAK4 overexpression and depletion, respectively,
specifically in the mouse mammary gland. PAK4 wt over-
expression caused hyperplasia and, at a later stage, mammary
tumors in a fraction of the mice comparable to the overexpression
of catalytically active PAK140. This incomplete penetrance as well
as the late tumor onset may suggest that similarly to PAK1, PAK4
itself acts as a relatively weak oncogene and/or to facilitate tumor
formation driven by other oncogene(s), the latter supported by
the activating KRAS mutations that we observed in these tumors
and the finding that PAK4 overexpression overcame RAS-
induced senescence in mammary epithelial cells.
The PAK4 conditional depletion was made in the context of
PyMT-driven mammary tumorigenesis. PyMT mice lacking
PAK4 developed mammary tumors significantly later than con-
trol mice. This was likely a consequence of the observed reduced
burden of hyperplasia and pre-malignant lesions detected in early
stage glands of PAK4-depleted animals. Also this impaired
PyMT-driven tumor initiation is consistent with a role for PAK4
in senescence evasion, an early event in tumorigenesis. This
notion is corroborated by our observations of a restored
senescence-like response in PAK4-depleted breast cancer xeno-
grafts and in PyMT tumors with conditional PAK4 knockout and
PyMT tumors treated in vivo with a PAK4 inhibitor that has
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proved successful in blocking the growth of multiple human
tumor xenografts34.
The restored senescence-like response in vivo upon PAK4
inhibition is supported by extensive in vitro phenotypic char-
acterization and transcriptome analyses employing a wide variety
of tools (siRNAs, shRNA, CRISPR/Cas9, and protein over-
expression). It is also in agreement with earlier reports showing
that PAK4 promotes cell cycle progression when overexpressed,
and hinders such progression when removed or inhibited19,20.
Beyond that, our data show that PAK4 inhibition almost
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invariably arrests cancer cell proliferation, while inducing addi-
tional senescence-like features (including morphological changes,
increased SA-β-gal activity, and gene expression changes indica-
tive of a senescent-like phenotype). Our data thus suggest that,
apart from glioblastomas28, epithelial cancer cells of various
origins require PAK4 to avoid senescence, adding to the idea of
generalized PAK4 addiction in cancer9.
NF-κB signaling has diverse and complex roles in cancer with
reports that NF-κB seems to both contribute to promotion and
suppression of tumorigenesis depending on the cellular context7.
However, while canonical NF-κB signaling (essentially via RELA)
has been extensively associated with the senescent phenotype8,41,
the potential role in senescence for the noncanonical NF-κB
pathway has remained elusive42. We identify PAK4 as an inhi-
bitor of NF-κB signaling in breast cancer and show that the
senescence-like growth arrest upon PAK4 knockdown in cancer
cells functionally requires the noncanonical NF-κB subunit RELB.
RELB is a known transcriptional target of both types of NF-κB
signaling7, meaning that the increased mRNA levels of NFKB1,
NFKB2, and RELB, as well as the activation of RELB could act in
synergy with increased RELB levels upon PAK4 depletion. Fur-
thermore, in line with recent studies that indicate that post-
translational modifications of NF-κB subunits play a critical role
in fine-tuning transcriptional activity, we identified PAK4 as a
RELB kinase. Adding to the four previously validated RELB
phosphosites43, we identified Ser151 as a PAK4-site within the
RHD of RELB, whose phosphorylation status regulated the
RELB binding to DNA and consequently, RELB transcriptional
activity. RELB–Ser151 phosphorylation prevented RELB interac-
tion with DNA possibly due to electrostatic repulsion with the
DNA phosphate backbone39. Such a modification may not only
affect the binding of different homo- or heterodimers of NF-κB to
cognate κB sites, but also regulate DNA-binding and release,
thereby fine-tuning transcription. It may also affect the recruit-
ment of various transcriptional coactivators and/or repressors to
the promoters of NF-κB target genes. The RELB–Ser151 PAK4
phosphorylation site also affected the expression of C/EBPβ,
whose expression is critical for senescence8. Growth arrested
PAK4-depleted cells show increased binding of RELB to DNA
consistent with a previous report of RELB–DNA-binding activ-
ities during therapy-induced senescence44. Interestingly, NF-κB
(explicitly RELA) and C/EBPβ can cooperatively regulate the
SASP8. Here we present a direct link between RELB and C/EBPβ,
raising the interesting question that these previously considered
distinct pathways may be regulated in an integrated manner to
control cell fate.
Further raising the potential clinical relevance, we found that
PAK4 is overexpressed across all breast cancer subtypes,
specifically upregulated during the disease development and
correlated with poor prognosis. In addition, we found that the
small fraction of patients carrying tumors that harbor PAK4
amplification tend to exhibit worse prognosis, suggesting that
although not a very frequent alteration, PAK4 amplification may
still be a clinically relevant feature. Importantly, we found that a
metagene signature of NF-κB signaling37, as well as RELB
expression itself, negatively correlated with PAK4 expression in
the METABRIC breast cancer patient dataset. These correlations
were only apparent in breast cancer but not in normal breast
tissue, adding to the notion that it may be possible to selectively
target the addiction to PAK4 of cancer cells. In addition, we show
that the low PAK4/high RELB pattern of expression correlates
with better prognosis in HER2-positive breast cancer patients.
This is consistent with the observation that HER2-positive
patients exhibited the highest PAK4 expression among the
PAM50 and IC10 breast cancer subtypes and also consistent with
the strong correlation observed between PAK4 expression and
HER2 signaling in the METABRIC dataset. PDCs were also
sensitive to PAK4 abrogation ex vivo while primary non-
immortalized HMECs were not, reemphasizing the notion of
PAK4 as a potential breast cancer treatment target.
In summary, our findings establish PAK4 as a promoter of
breast cancer development, possibly through overcoming the
barrier of OIS. By showing also a competitive advantage con-
ferred by PAK4 to established breast cancer cells, acting through
the noncanonical NF-κB signaling subunit RELB to prevent
senescence-like growth arrest, we reveal a selective vulnerability
of cancer cells to PAK4 inhibition that may be explored as a
therapeutic strategy.
Methods
Mice. All experimental animal procedures in this study were performed in
accordance with Swedish and European Union guidelines and approved by the
institutional ethical commissions (Stockholms Södra and Linköpings djurförsök-
setiska nämnder S39-09; S169-09; S86-11; S23-12; S169-12; S66-14 and 42-16).
Animals were housed in group in standardized cages with a 12:12 h light:dark
cycle with unrestricted access to food and water. At the experimental endpoint,
animals were sacrificed by cervical dislocation after isoflurane anesthesia. Both
males and females were used as specified in each section.
To generate the MMTV-myc-PAK4 sequence, we amplified by PCR the coding
sequence of mouse PAK4 from a commercial cDNA clone IRAVp968C0391D
(Sourcebiosciences) and cloned the amplified cDNA in pcDNA vector containing
myc tag sequence at the 5′ end of the multiple cloning site. Then, we isolated the
myc-PAK4 fragment by digestion with KpnI and NotI, and inserted it into the
pspT2 MMTV–LTR plasmid (a kind gift from M. Glukova, Paris). The MMTV-
myc-PAK4 sequence was isolated from the vector by digestion with SalI, gel
purified, and microinjected at 3.4 ng/µL in the pronucleus of fertilized oocytes from
FVB/NJ mice (Charles River) according to standard protocols. MMTV–PAK4 is
available upon request for noncommercial use.
Fig. 7 RELB–Ser151 phosphorylation controls DNA-binding and C/EBPβ transcription. a Structure of RELB:κB DNA complex (PDB ID: 3DO7) highlighting
RELB–Ser151 in close proximity to DNA, the RELB subunit shown in purple and DNA in greens. Top inset zooms into Ser151 and shows a hydrogen bond
with the DNA backbone. Bottom inset models the disturbing impact on DNA binding of Ser151 phosphorylation. b ELISA-based measurements of
RELB DNA-binding 24 h upon expression of the indicated constructs in Hs 578T cells (n= 3 per group). c Representative immunoblot for experiments
quantified in b using VINCULIN as loading control. d ELISA-based measurements of RELB DNA-binding in MCF7 cells stably expressing the indicated
constructs (n= 4 per group). e ELISA-based measurements of RELB DNA-binding 4 days after the indicated siRNA transfections in Hs 578T cells (n= 3
per group). f Differentially expressed genes from an RT-qPCR array performed in Hs 578T cells transfected with FLAG-tagged RELB–S151E and RELB-wt
(n= 3 per group). Statistically discernible hits (Supplementary Fig. 7c) are ordered by Fold Change. g Correlation between the expression of C/EBPβ and
RELB in tumors (T) and normal tissue (N) in METABRIC. h RT-qPCR analyses of C/EBPβ mRNA in Hs 578T cells 72 h after the indicated siRNA
transfections (n= 3 per group). i Quantification of EdU+ cells in Hs 578T cells 4 days after the indicated siRNA transfections (n= 3 per group). j Schematic
summary diagram. In proliferating cancer cells, abundant PAK4 contributes to senescence avoidance. PAK4 inhibits RELB by direct interaction and
phosphorylation of RELB–Ser151 thereby impairing binding affinity to DNA. In the absence of PAK4, RELB accumulates and binds DNA, which culminates in
the expression of senescence regulators including C/EBPβ. Data are represented as mean ± SEM in b, d, e, h, and i. p-values by one-way ANOVA followed
by Tukey's post hoc test in b and by two-tailed unpaired t tests in d, e, h, and i are indicated. The Spearman correlation and p-value by Spearman’s test are
indicated in g for tumors (T, blue, n= 1992) and normal tissue (N, gray, n= 144)
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Transgene integration was tested via PCR analysis of genomic DNA, with the
MMTV–PAK4 primers 5′-TTTGGAAAGAAGAAGAAGC-3′ and 5′-ACTGCC
ACTGCCTGCCTCAC-3′, amplifying a band of 441 bp.
A cohort of 36 virgin females (n= 16 wt FVB and n= 20 MMTV–PAK4) was
monitored for the development of mammary tumors up to 24 months of age to
determine tumor incidence.
PAK4fl/fl mice (B6.129S2(FVB)-Pak4tm2.1Amin/J, gift from Audrey Minden,
Rutgers University, NY, USA)24 were crossed with MMTV-Cre/Line D mice
(Tg(MMTV-cre)4Mam/J, Jackson Laboratory)25 and then bred to MMTV–PyMT
(B6.FVB-Tg(MMTV-PyVT)634Mul/LellJ, gift from Lars Holmgren, Karolinska
Institutet, Stockholm, Sweden)45. All mice were maintained on B6 background.
Cohorts of virgin MMTV–PyMT;MMTV-Cre;PAK4fl/fl (PyMT;PAK4MEp−/−)
and MMTV–PyMT;MMTV-Cre (PyMT;PAK4MEp+/+) were used to study the
effects of conditional PAK4 depletion in mammary tumorigenesis. For tumor-free
survival analyses female mice were monitored for tumors by weekly palpation after
the age of 2 months. The endpoint for survival analysis was taken as the time at
which the combined tumor burden surpassed the ethical guidelines in our permit.
The presence of the PyMT and Cre transgenes and the heterozygous or
homozygous knockout of Pak4 was verified through genotyping. Genomic DNA
was prepared from either ear or tail biopsies using the fast tissue–to-PCR kit
(#K1091, Fermentas) and PCRs ran according to the Jackson Laboratory suggested
protocols. Genotypes were visualized on 1–2.5% agar gels stained with GelRed
(41003, Biotium). The primer pairs used (synthesized by ThermoFisher) were as
follows: Pak4: 5′-CGGATATTGTCACCCACACCA-3′ and 5′-CTAACAGGGACA
GGAGCT-3′; Cre: 5′-GGTTTCCCGCAGAACCTGAAG-3′ and 5′-GCTAGTGCC
TTCTCTACACC-3′; and PyMT: 5′-GGAAGCAAGTACTTCACAAGGG-3′ and
5′-GGAAAGTCACTAGGAGCAGGG-3′.
Female 10–15-week-old MMTV–PyMT (FVB/N-Tg(MMTV–PyVT)634Mul/J)21
were used to evaluate PAK4 expression in mammary tumors and adjacent
mammary tissue and to study the intratumoral effects of PF-03758309.
Female 6–8-week-ld BALB/c mice (CAnN.Cg-Foxn1nu/Crl, Charles River) were
used in the xenograft model. BALB/c mice acclimatized for 1 week before being
randomly assigned per experimental condition.
Cell lines. HMEC (batches #1 and #2), Hs 578T, BT-549, MCF7, MDA-MB-231,
T-47D, OVCAR-3, Caov-3, and TOV-21G were obtained from the American Type
Culture Collection (ATCC). SUM-159 cells were obtained from Asterand. AsPC-1,
PANC-1, and MIA Pa-Ca-2 were obtained from the European Collection of
Authenticated Cell Cultures. These pancreatic cancer cells and Paca346 were a
generous gift from Rainer Heuchel and Matthias Löhr, Karolinska Institutet,
Huddinge, Sweden. Cells were tested for mycoplasma but not subjected to addi-
tional cell authentication. HMECs were grown in Mammary Epithelial Cell Growth
Medium (MEGM, CC-3051, Lonza) supplemented with MEGM BulletKit (CC-
3150, Lonza). Hs 578T, MCF7, MDA-MB-231, PANC-1, and MIA Pa-Ca-2 cells
were grown in Dulbecco’s Modified Eagle’s Medium that contains 4,5 g/L glucose
and 4 mM L-glutamine (DMEM, 41965, Life Technologies) supplemented with 10%
Fetal Bovine Serum (FBS, 10270, Life Technologies). BT-549, T-47D, AsPC-1 and
Paca3 cells were grown in RPMI-1640 (42401, Life Technologies) supplemented
with 2 mM L-glutamine (25030, Life Technologies) and 10% FBS. OVCAR-3 cells
were grown in RPMI-1640 supplemented with 2 mM L-glutamine, 20% FBS, and
0.01 mg/mL bovine insulin (I5500, Sigma). Caov-3 were grown in DMEM sup-
plemented with 10% FBS and 1 mM sodium pyruvate (11360, Life Technologies).
TOV-21G were grown in a 1:1 mixture of MCDB 105 medium (M6395, Sigma) and
Medium 199 (M0650, Sigma) supplemented with 15% FBS. SUM-159 cells were
grown in Ham’s F-12 Nutrient Mix (11765, Life Technologies) supplemented with
5% FBS, 10 ng/mL epidermal growth factor (EGF, PHG0311, Life Technologies), 5
μg/mL insulin (I5500, Sigma), 1 μg/mL hydrocortisone (H0888, Sigma), and 10
mM HEPES (15630, Life Technologies). HMECs harboring 4-Hydroxytamoxifen
(OHT)-inducible RASG12V 32, kindly provided by David Beach, Barts and The
London School of Medicine and Dentistry, UK, were grown in phenol red-free
Mammary Epithelial Basal Medium (CC-3153, Lonza) supplemented with MEGM
BulletKit (CC-3150, Lonza). These cells display a classical senescence phenotype
upon treatment with 12.5 nM OHT (H7904, Sigma). MCF7 cells stably expressing
shControl or shPAK4 have been previously described47 and were grown in DMEM
supplemented with 10% FBS and 150 μg/mL G418 (11811, Life Technologies).
Stably-transfected MDA-MB-231-derived cell lines were generated by electro-
poration using the Neon Transfection System (ThermoFisher). Briefly, EGFP,
EGFP–PAK4-wt, and EGFP–PAK4–siRNA resistant constructs and the pGL4.21
vector (E6761, Promega) containing a PuroR cassette were co-transfected using the
electroporation parameters as suggested by the manufacturer. After 48 h recovery
in complete medium, cells were seeded at low density in medium containing
2 μg/mL puromycin (P8833, Sigma). This dose was effective for killing non-
transfected cells. Cells were expanded and grown to bulk cultures in the presence of
the selection antibiotic. EGFP-positive cells were subsequently enriched by sorting
on a BD FACSAria flow cytometer. Unique stable cells are available upon request
for noncommercial use.
All cells were maintained at 37 °C, 5% CO2, and 3% O2 in their specified growth
medium.
Patient-derived primary breast cancer cells. Fresh scrapings were collected from
primary breast cancer after surgical procedures in compliance with approved
ethical permit. Permits were obtained from the regional ethics board at Karolinska
Institutet in Stockholm and from the Stockholm medical biobank (ethical approval
#02–061 with amendments 2013–1065–32 and 2015–2259; and ethical approval
2016/957–31 with amendment 2017/742–32). All patient material was anonymized.
Single cells were generated immediately as previously described48. Cells were then
differentiated in DMEM/F-12 GlutaMAX medium (10565, Life Technologies)
supplemented with 5% FBS, 10 ng/mL epidermal growth factor (EGF, PHG0311,
Life Technologies), 5 μg/mL insulin (I5500, Sigma), 1 μg/mL hydrocortisone
(H0888, Sigma), and 10 μg/mL cholera toxin (C8052, Sigma). All the experiments
were performed within five generations of these cultures that were then discarded.
Murine-derived primary breast and pancreatic cancer cells. The PyMT murine
breast cancer cell line (PeRo-Bas1) was established from a FVB/N PyMT tumor31.
Briefly, the tumor tissue was chopped in small fragments, suspended in DMEM
(41965, Life Technologies) supplemented with 10% FBS and 100 U/mL penicillin-
streptomycin (15140, Life Technologies) and filtered through a 100 μm cell strainer
to remove bigger tissue parts. Cells were cultured overnight. Cell debris and con-
taminating immune cells or erythrocytes were removed through media change and
phosphate-buffered saline (PBS) washes. Culture was continued until the cells
reached 75% confluence, when contaminating fibroblasts were removed through
brief trypsin treatment.
The KPC murine pancreatic cancer cell line32 was grown in DMEM/F-12
(11320, Life Technologies) supplemented with 10% FBS and 100 U/mL
penicillin–streptomycin (15140, Life Technologies).
Xenograft model. In total, 2 × 106 MCF7 cells stably expressing shControl (n= 8)
or shPAK4 (n= 10) were suspended in growth factor-reduced Matrigel/PBS (100 μl,
50% final concentration, 356230, Becton Dickinson) and subcutaneously (s.c.)
inoculated at the right flank of 6–8-week-old BALB/c female mice. Mice were
implanted with 17β-estradiol pellets (0.72 mg per pellet, 90-day release, NE-121,
Innovative Research of America) prior to the s.c. injection. After 9 days, when the
cells started to form palpable tumors, xenograft size was determined regularly by
externally measuring the growing tumors in two dimensions using an electronic
caliper. Tumor volume (V) was approximated by the equation V=½ (L×W^2),
where L is the length and W is the width of the xenograft. All mouse experiments
were done in a blinded fashion with mice being randomly selected for experiments.
The person performing the measurements was blinded to the treatment groups. At
the end of the experiment, xenografts were resected, photographed, weighted, and
processed according to subsequent analyses.
Intratumoral injection of PF-03758309. PF-03758309 has been previously
characterized as a PAK4 inhibitor34. PF-03758309 (Anthem Biosciences, Banga-
lore, India) was dissolved in dimethyl sulfoxide (DMSO, D5879, Sigma).
The compound was administered intratumorally at 6 mg/kg body weight in 100
μl of PBS to 10-week-old MMTV–PyMT females (FVB/N) with palpable tumors
(n= 8). The largest palpable tumor at the experimental starting point was injected
daily for 5 consecutive days. Vehicle animals (n= 5) received the same number of
injections of the solvent. At the experimental endpoint, tumors were harvested and
processed according to subsequent analyses.
Small-interfering RNAs (siRNAs). The siRNAs used in this study were synthe-
sized by Qiagen, Life Technologies and Genepharma. siRNA targeting sequences
were as follows: PAK4#1: AACGAGGTGGTAATCATGAGG, PAK4#2: CGAGAA
TGTGGTGGAGATGTA, RELB#1:
UGCUGAACACCACUGAUAUGUCCUC, RELB#2: AAUUGGAGAUCAUC
GACGAGU, CEBPB#1: CCGCCUGCCUUUAAAUCC, CEBPB#2: GGCCCUGA
GUAAUCGCUU, PAK4m#1: CAGAGACGACACTATGAGAAA, PAK4m#2: TT
CGTGGGACCTACTACTGAA, Control: AAGCGCGCTTTGTAGGATTCG or
AllStars Negative Control siRNA (Qiagen, cat#SI03650318).
sgRNAs. For CRISPR/Cas9-mediated PAK4 gene ablation, two single guide (sg)
RNA sequences against PAK4 (sgPAK4#1: 5′-TGATCGAGGAGTCGGCTCGC-3′
and sgPAK4#2: 5′-GTGCACGCGGTGCTCGAAGT-3) were designed with
CRISPR DESIGN49 (http://crispr.mit.edu). Plasmids for the lentivirus vector-
mediated CRISPR-Cas9 (lentiCRISPRv2, cat#52961) and packaging (pCMV-VSV-
G, cat#8454 and psPAX2, cat#12260, generously provided by Eyal Gottlieb, The
Beatson Institute, Glascow, UK). Oligonucleotides for sgRNA were annealed and
cloned into the lentivirus transfer vector lentiCRISPRv2 at the BsmBI restriction
site50 and the specific target sequence was verified by DNA sequencing.
Plasmids and mutagenesis. FLAG–PAK4, FLAG–BAP, EGFP, EGFP–PAK4 wt,
and EGFP–PAK4–M350 constructs have been previously described51.
An siRNA-resistant form of PAK4 was generated by site-directed mutagenesis
using the QuikChange Site-Directed Mutagenesis Kit (200518, Agilent) and the
EGFP–PAK4 construct. The silent mutations were introduced into the siRNA
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target region using the following primers: 5′-GCTCTTCAACGAGGTTGTTATCA
TGAGGGAC-3′ and 5′-GTAGTCCCTCATGATAACAACCTCGTTGAAG-3′.
FLAG-tagged human RELB (FLAG-RELB-wt) was constructed by cloning the
full-length human RELB cDNA52 (gift from Sam Okret, Karolinska Institutet,
Huddinge, Sweden) into the vector p3 × FLAG-CMV-10 (E4401, Sigma) within
HindIII and KpnI restriction sites to fuse them in N-terminal with FLAG. The
primers used were 5′-TAGAAGCTTATGCT
TCGGTCTGGGCCAGCC-3′ and 5′-GTAGGTACCCTACGTGGCTTCAGGCCC
CGGGG-3′. The FLAG-tagged RELB mutants S151A and S151E (FLAG-RELB-
S151A and FLAG-RELB-151E) were created by site-directed mutagenesis using the
QuikChange Site-Directed Mutagenesis Kit (200518, Agilent). For S151A the
following primers were used: 5′-GAGGGCCGCTCGGCCGGCGCCATCCTTGG
GGAGAGC-3′ and 5′-GCTCTCCCCAAGGATGGCGCCGGCCGAGCGGCCC
TC-3′. For S151E the following primers were used: 5′-GAGGGCCGCTCGGCCGG
CGAGATCCTTGGGGAGAGC-3′ and 5′-GCTCTCCCCAAGGATCTCGCCGGC
CGAGCGGCCCTC-3′.
GST-tagged murine RELB-N, -C, and -RHD (provided by Ralf Marienfeld,
University of Würzburg, Würzburg, Germany) have been previously reported53.
hRELB aa102–400 was PCR amplified from hRELB cDNA and cloned into the
pGEX-4T-1 vector (28–9545–49, GE Healthcare) (named GST-RHD) within EcoRI
and NotI restriction sites using the following primers: 5′-AAGGTAGAATTCGCC
ACGCCGCCGCCTTGG-3′ and 5′-GAGTAGCGGCCGCCTAGCGAGGCAGGT
ACGTGAAAGG-3′. GST-RHD-S151A was created by site-directed mutagenesis
using the QuikChange Site-Directed Mutagenesis Kit (200518, Agilent) as above.
The sequences of all primers used in this study can be found in Supplementary
Table 5.
To construct His–PAK4 expression vector, full-length human PAK4 including a
Strep II tag was amplified by PCR and cloned into pET15b (69661–3, EMD
Millipore) within NdeI and BamHI restriction sites to fuse it in N-terminal with
6 × His-tag.
All constructs have been sequenced.
Transient transfection of siRNAs and plasmids. Cancer cells were reverse
transfected with siRNAs (10–30 nM) using Lipofectamine RNAiMAX transfection
reagent (13778, Invitrogen) according to the manufacturer's instructions.
HMECs were transiently transfected with siRNAs using the HMEC
Nucleofector Kit (VPK-1002, Lonza) according to the manufacturer’s instruction.
Program Y-001 was used for higher transfection efficiency.
Cells were transiently transfected with expression plasmids using Attractene
transfection reagent (301005, Qiagen) or Lipofectamine 2000 or 3000 (11668 or
L3000, Invitrogen) according to the manufacturer’s suggestion. Routinely 8 μg of
DNA was transfected for each 100 mm cell culture dish.
Cells were harvested for the various experimental purposes at the timepoints
specified in the figures. The efficiency of gene suppression/expression was
monitored after transfection by immunoblot, RT-qPCR, or immunostaining.
CRISPR/Cas9 gene editing. For PAK4 gene ablation, we established BT-549 cells
with stable expression of Cas9 and two single guide RNA sequences against PAK4
(sgPAK4). Specifically, lentiviral particles expressing sgPAK4 were generated in
HEK293T cells by co-transfecting lentiCRISPRv2 vector, psPAX2, and pCMV-
VSV-G at a ratio of 4:3:2 using Lipofectamine 2000 (11668, Invitrogen). After 24 h,
the media was replaced with fresh media. The supernatant containing the viral
particles was collected every 24 h for 2 days, filtered through a 0.45 μm pore
membrane (83.1826, Sarstedt), and centrifuged 45 min at 1500 g at 4 °C with the
Lenti-X concentrator (631231, Clontech). The pellet, containing viral particles, was
dissolved in medium and used for cell infection. Cells were transduced in 2 mL of
media with 100 μl of viral supernatant in six-well plates. At 48 h post transduction,
cells were selected with 1 μg/mL puromycin (P8833, Sigma) for 48 h, and then cells
were expanded in the regular culture medium and used for assays at the timepoints
specified in the figures. The effectiveness of CRISPR gene knockout was confirmed
by immunoblotting with the indicated antibody.
SA-β-gal activity. For cultured cells, SA-β-gal staining was performed at the
indicated time points using the Senescence β-Galactosidase Staining Kit (9860, Cell
Signaling) or as described previously29. Images were acquired with a Nikon
widefield, 10 × 0.45 NA air objective and MMI cell scan software. Regions of
interest were selected according to a standardized pattern, in which X-Gal+ (5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and the total number of cells
were manually counted in ImageJ/Fiji using the Cell Counter plugin (National
Institutes of Health, NIH) to determine the percentage of X-Gal+ cells.
An additional quantitative assay of SA-β-gal activity using cell extracts was
employed as previously described30. This method uses 4-Methylumbelliferyl-β-D-
galactopyranoside (MUG, M1633, Sigma) as substrate instead of X-Gal. The
fluorescent product was measured using an automated plate reader (SpectraMax
Gemini, Molecular Devices) with excitation at 360 nm and emission at 465 nm.
SA-β-gal staining of cryosections was performed on freshly harvested tissues at
the experimental endpoint. Briefly, after resection, tumors were immediately snap
frozen in liquid nitrogen, embedded in OCT cryomount (45830, Histolab),
cryosectioned (4-μm thickness), and mounted onto SuperFrost Plus slides
(631–0108, VWR). Slides were immersed in fixation solution containing 2%
formaldehyde (F1635, Sigma)/0.2% glutaraldehyde (G7776, Sigma) in PBS for
5 min at room temperature, washed with PBS, and stained in 40 mM citric acid/
sodium phosphate (pH= 5.5) containing 1 mM MgCl2, 1 mg/mL X-Gal (B9146,
Sigma), and 5 mM of each potassium ferricyanide (P-8131, Sigma) and potassium
ferrocyanide (P-3289, Sigma) at 37 °C. Slides were counterstained with eosin
(01650, Histolab) and imaged on a Zeiss Axiovert 100 inverted microscope. Images
were deconvoluted with ImageJ/Fiji (National Institutes of Health, NIH) using the
Color Deconvolution plugin54. The area occupied by X-Gal staining was
thresholded and presented as a percentage of the total tissue area. The X-Gal+ area
calculated per animal represents the average of two independent sections per tumor
and the quantification of 2–10 nonoverlapping areas per section.
SA-β-gal staining of xenografted MCF7 tumors was performed on tissue slices
of ~1-mm thickness, fixed in 2% formaldehyde/0.2% glutaraldehyde in PBS for 5
min at room temperature for immediate free-floating SA-β-gal whole-mount
staining in the solutions described above. Tissues were then photographed and the
X-Gal+ area was determined as specified above for cryosections.
SA-β-gal staining of PyMT-driven early lesions was performed on whole
mammary glands using the free floating SA-β-gal wholemount staining approach
described above. X-Gal-stained mammary glands were then sectioned (4-μm
thickness), counterstained with hematoxylin and imaged on Pannoramic MIDI II
slide scanner from 3DHISTECH. Fifteen lesions per animal in close proximity to
the nipple were selected and the number of X-Gal+ as well as the total number of
cells per lesion were manually counted for determination of the percentage of X-
Gal-positive cells per lesion.
Immunostainings. Xenografted tumor tissue was embedded in OCT (45830,
Histolab), cryosectioned (10-μm thickness), and mounted onto SuperFrost Plus
slides (631–0108, VWR). Sections were immersed in fixation solution containing
4% formaldehyde (F1635, Sigma) in PBS for 5 min at room temperature, washed
with PBS and incubated with blocking solution consisting of 10% normal donkey
serum (017–000–121, Jackson ImmunoResearch) in PBS with 0.3% Triton X-100
(X100, Sigma) for 1 h at room temperature. Sections were then incubated at 4 °C
overnight in a humidified chamber with primary antibodies diluted in 10% normal
donkey serum in PBS. Slides were probed with AF488-conjugated α-p53 (1:100,
DO-1 #sc-126 AF488, Santa Cruz) and α-Ki67 (1:250, #ab15580, AbCam). After
washing, antibody labeling was revealed using species-specific fluorophore-con-
jugated secondary antibodies (1:500, Rhodamine Red-X goat anti-rabbit IgG,
111–295–144, Jackson ImmunoResearch or Oregon Green 488 goat anti-Rabbit
IgG, O-11038, ThermoFisher) in 10% donkey serum in PBS for 1 h at room
temperature. Sections were counterstained with Hoechst 33342 (14533, Sigma).
Images were acquired using a Nikon A1R confocal microscope with a Plan Apo VC
60×/1.4 NA oil objective and NIS-Elements software (Nikon).
Mammary tissues harvested from the transgenic mouse models were paraffin-
embedded and sectioned at 4-μm thickness. For immunohistochemistry, sections
were deparaffinized by incubation at 60 °C for 1 h followed by rehydration steps
through washing in xylene and graded ethanol to distilled water. Samples were
boiled for 20 min in antigen retrieval solution 0.01 M sodium citrate buffer
(100813M, BDH) (pH 6.0) in water. Endogenous peroxidase activity was blocked
via treatment with 3% hydrogen peroxide in water (H1009, Sigma). PBS diluted
normal serum from the same host species as the secondary antibody was used as a
blocking buffer. Slides were incubated at 4 °C overnight in a humidified chamber
with a α-Cre antibody (1:100, PRB-106P, Covance) or newly generated α-PAK4
#73 antibody diluted 1:100 in blocking buffer. After three times PBS washing, slides
were incubated at room temperature for 1 h with Biotin-SP-AffiniPure Goat α-
Rabbit IgG (1:400, 111–065–144, Jackson ImmunoResearch) followed by three
washes with PBS and then were incubated room temperature for 20 min with HRP-
conjugated Streptavidin (016–030–084, Jackson). Following three washes with PBS,
development was performed with diaminobenzidine (DAB, K3467, DAKO
Sweden). Then slides were counterstained with Mayer HTX staining solutions
(01820, Histolab), dehydrated, and mounted using DPX mounting media (44581,
Sigma). Images were acquired on Pannoramic MIDI II slide scanner from
3DHISTECH. Scanned slides were further quantified using the HistoQuant module
in Panoramic Viewer (3DHISTECH). H-Score was automatically calculated by the
software using the following formula: H-Score= (1+ i)Pi (where i is intensity
score and Pi is the percentage of positivity).
In situ hybridization (ISH) of PAK4 mRNA expression. In situ hybridization for
PAK4 RNA transcripts was performed using the RNAscope 2.0 High Definition
assay (Advanced Cell Diagnostics). Assays and quantifications were performed
according to the manufacturer’s instructions using a specific probe set against
murine PAK4 (Probe: Mm-PAK4). Positive and negative controls were Mm-Polr2a
(312471) and dapB (310043), respectively. Slides were scanned using Pannoramic
MIDI II from 3DHISTECH. Scanned slides were compared with positive and
negative probes and were scored from very low expression (score 1) to highly
expressed (score 3).
Cell proliferation assay. At the specified timepoints, cells growing on glass or
plastic substrates, were cultured at 37 °C for 1 to 2 h in the presence of 30 μM 5-
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ethynyl-20-deoxyuridine (EdU, Life Technologies) or 30 μM 5-Bromo-2'-deox-
yuridine (BrdU, B5002, Sigma). Cells were fixed and assayed for EdU incorporation
using an EdU Assay kit (C10635, Life Technologies) according to the manu-
facturer’s instructions or cells were fixed and stained for BrdU using α-BrdU mAb
G3G4 (1:100, G3G4, Developmental Studies Hybridoma Bank, Department of
Biological Sciences, University of Iowa, Iowa City, IA) as described previously.
EdU/BrdU imaging was performed on a Nikon A1R confocal microscope using
a Plan Apo γ 20X/0.75 NA air objective, producing a pixel resolution of 0.82 μm. In
total, 3 × 3 or 4 × 4 image montages were acquired and stitched. Nuclear outlines
were identified using Hoechst 33342 (14533, Sigma) staining. The percentage of
EdU/BrdU+ cells in total cells was analyzed with the NIS-Elements software
(Nikon).
For EdU/BrdU analysis by flow cytometry a minimum of 10,000 events was
analyzed on a BD FACSCalibur or a BD FACSCantoII.
HMECs harboring 4-Hydroxytamoxifen (OHT)-inducible RASG12V were EdU-
stained and analyzed by FACS 48 h after transient transfection with the indicated
plasmids and simultaneously treated with 12.5 nM OHT (H7904, Sigma) or vehicle.
Colony formation assay. For colony formation assays on plastic six-well plates,
cells were replated 4 days after lentiviral infection at single cell density (15,000 cells
per well) in regular cell culture medium. At the indicated timepoints post-seeding,
cells were rinsed twice with PBS, fixed with 4% formaldehyde (F1635, Sigma) for
20 min at room temperature and stained with 0.01% Crystal Violet in ddH2O
(0.01% [w/v], C3886, Sigma) for 30 min at room temperature. Plates were then
washed extensively and allowed to dry. Plates were scanned and analyzed with
ImageJ/Fiji software (National Institutes of Health, NIH) using the Colony Area
plugin55.
Mammary gland wholemounts and sections. The #4 inguinal mammary glands
were dissected from 12 weeks old female mice (n= 6 per genotype), wholemounted
onto SuperFrost Plus slides (631–0108, VWR), fixed in Carnoy’s fixative (60%
ethanol, 30% chloroform, and 10% glacial acetic acid) for 2 h at room temperature,
stained with a solution of carmine (C1022, Sigma) and aluminum potassium sulfate
(A7167, Sigma) overnight at room temperature, de-stained in 70% ethanol, further
washed in 100% ethanol, cleared of fat in xylene (28975, VWR) overnight and
mounted using DPX (44581, Sigma) or stored in xylene until scanning. ImageJ/Fiji
(National Institutes of Health, NIH) was used for morphometric analysis. Raw
images were cropped to include only the fourth mammary gland, converted to 8-bit
and sharpened. The area occupied by carmine staining (mammary epithelium) was
thresholded and presented as a percentage of the total mammary fat pad area.
Paraffin-embedded tissues (sectioned at 4-μm thickness) were routinely stained
with hematoxylin and eosin for morphological evaluation according to standard
procedures.
Cell lysis. Adherent or pelleted cells harvested by trypsinization (15400, Ther-
moFisher) were washed with PBS and lysed on ice in cold PAK-lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 10% glycerol, and 1% NP-
40) or PBSTDS lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 0.14M NaCl, 2.8 mM KCl, 10 mM Na2HPO4, and
1.5 mM KH2PO4) containing freshly added cOmplete protease (1697498, Sigma)
and phosphatase (P0044, Sigma) inhibitors cocktails.
Total protein from snap frozen mouse tissues was extracted with RIPA buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycolate,
and 0.1% SDS) supplemented with protease and phosphatase inhibitor cocktails
as above.
To prepare nuclear extracts, cells were lysed with cytoplasmic buffer (10 mM
HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2 and freshly added protease and
phosphatase inhibitors as above), incubated on ice for 15 min, homogenized in a
glass Dounce homogenizer with 30 strokes of a tight-fitting glass pestle Kontes B,
and checked under the microscope to verify that 95% of the cells displayed trypan
blue (T8154, Sigma) staining. Nuclei were pelleted by centrifugation at 350 g for 5
min at 4 °C, washed with cytoplasmic buffer three times, dissolved in nuclear buffer
(20 mM HEPES, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and
freshly added protease and phosphatase inhibitors) and kept on ice for 30 min
before vigorous vortexing. Nuclear extracts were then cleared at 16,000 g for 20 min
at 4 °C.
Protein concentration was determined with the Pierce bicinchoninic acid assay
(23225, ThermoFisher) kit according to the manufacturer’s instructions.
Cell extracts were denatured by boiling at 95 °C upon addition of 5× SDS
loading buffer (10% SDS, 20% glycerol, 0.05% bromophenol blue, 0.2 M Tris-HCl
pH 6.8, and 10 mM β-mercaptoethanol). Otherwise, cells were lysed directly in 2×
SDS loading buffer.
Immunoblotting. Equal amounts of denatured protein were subjected to 10% SDS-
PAGE (SDS-polyacrylamide gel electrophoresis) using molecular weight markers
(26619, Fermentas) to confirm the expected size of the target proteins and trans-
ferred to PVDF membranes (IPVH00010, Millipore). Membranes were washed in
TBST buffer (TBS containing 0.1% Tween-20) and nonspecific binding sites were
blocked by immersing the membranes in blocking buffer containing 4% nonfat
milk (70166, Sigma) in TBST buffer for 1 h on a shaker at room temperature or
overnight at 4 °C. Membranes were probed with the following primary antibodies:
α-PAK4 pab 6508 (1:1000), α-RELB (1:1000, C1E4 #4922, Cell Signaling; 1:1000,
#06–1105, Millipore; 1:1000, EP613Y #GTX61291, Genetex and 1:1000, clone 17.3
#LS-C354950–100, LSBio), α-p53 (1:1000, DO-1 #sc-126, Santa Cruz); α-p21
(1:1000, C19 #sc-397, Santa Cruz); α-ACTIN (1:1000, JLA20, Developmental
Studies Hybridoma Bank - DSHB); α-VINCULIN (1:100000, #V9131, Sigma); α-
GAPDH (1:50000, #MAB374, Millipore) and α-pRb (1:1000, #554136, BD-Phar-
mingen). Antibodies against ACTIN, VINCULIN, GAPDH, and pRb served as
control for protein loading. Next, appropriate peroxidase-conjugated anti-mouse
(715–035–150, Jackson ImmunoResearch) or anti-rabbit (111–035–144, Jackson
ImmunoResearch) secondary antibodies were used diluted 1:3000.
Bound antibodies were visualized with the Pierce enhanced chemiluminescence
Plus Western Blotting Substrate detection system (32132, ThermoFisher) according
to the manufacturer’s instructions.
Quantity One analysis software (Bio-Rad) and ImageJ/Fiji (National Institutes
of Health, NIH) were used for densitometric analysis of western blots.
Quantification results were background subtracted and normalized to a loading
control.
Uncropped and unprocessed scans of all blots are supplied in the Source
Data file.
Co-immunoprecipitations. Immunoprecipitations were performed by incubating
the same amount of the relevant whole-cell lysates with the appropriate antibodies
(500–1000 μg of whole cell lysate, 2 μg of antibody) overnight at 4 °C with gentle
agitation to allow immunocomplexes to form. Prior to incubation with the spe-
cified antibodies, samples were precleared by incubation with protein G-Sepharose
beads (sc-2002, Santa Cruz) and 2 μg of α-mouse IgG (I5381, Sigma), for 1 h at
4 °C. Following the overnight incubation and when applicable, the immunocom-
plexes were collected by the addition of protein G-Sepharose beads for 3 h at 4 °C
and washed six times with lysis buffer. Proteins were eluted by boiling in 2× SDS
loading buffer and eluates were resolved on a 10% SDS-PAGE for immunoblotting
with relevant antibodies. Unless otherwise indicated, FLAG-tagged proteins were
immunoprecipitated with EZview Red ANTI-FLAG M2 Affinity Gel (F2426,
Sigma). Otherwise, the following antibodies were used: monoclonal mouse α-PAK4
(clone OTI1C7 #CF807297, Origene), monoclonal mouse α-RELB (clone 17.3 #LS-
C354950–100, LSBio), and α-mouse IgG (I5381, Sigma) as control.
NF-κB DNA-binding activity. DNA-binding activity of the mammalian NF-κB
subunit RELB was measured in 20 μg of nuclear extracts using the TransAM NF-κB
Family transcription factor assay kit (11467468, Active Motif) in accordance with
the manufacturer’s protocol.
Exome sequencing. Genomic DNA was extracted from flash-frozen liver tissue
and from three mammary tumors that arose in virgin MMTV–PAK4 female mice
(20–24 months old) using the DNeasy Blood & Tissue Kit (69504, Qiagen) as
specified by the manufacturer. DNA concentrations were determined using an
Infinite®200 PRO (Tecan) plate reader. SOLiD Fragment Standard Library Builder
and SureSelect Mouse Exome kit (Agilent) were used according to the manufac-
turer's protocol to prepare samples for WES performed on a SOLiD 5500 machine
at Science for Life Laboratories, Uppsala, Sweden, producing unpaired,
matched reads.
Exome sequencing reads were aligned to the mouse mm9 genome using BWA
(bio-bwa.sourceforge.net/) with additional processing using Picard (broadinstitute.
github.io/picard/) and Samtools56. Somatic variants were called using MuTect57
and annotated using Annovar58.
RNA sequencing. Total RNA was isolated from Hs 578T and BT-549 cells 72 h
after transient transfection with PAK4-targeting (siPAK4#1) or control siRNA
using the RNeasy Mini Kit (74104, Qiagen) as specified by the manufacturer. RNA
quality was assessed with Agilent 2100 Bioanalyzer (Agilent Technologies) prior to
high-throughput mRNA-sequencing of poly-adenylated transcripts from total
RNA using paired end sequencing on an Illumina HiSeq2000 platform. Library
construction and sequencing was performed at the SciLifeLab in Stockholm.
Paired end reads were aligned to the human genome (hg19) using Tophat259
retaining only uniquely mapping reads. Reference splice junctions were provided
via reference transcriptome (Ensembl build 73). Explicit read abundance at each
transcript model was assessed using HTSeq (python) prior to calling differential
expression with DESeq260. Significance thresholds were considered using an FDR
corrected p-value ≤ 0.05. FPKM values (fragments per kilobase of exon model per
million mapped fragments) were calculated using Cufflinks61. Figures were
generated using the ggplot2 package in R. Gene ontologies were analyzed through
the use of IPA27 (QIAGEN Inc).
The list of NF-κB target genes was derived from a third party dataset (in fetal
lung fibroblasts—https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSM1055810). Here, raw sequences were aligned against the hg19 human
genome using bowtie2 and peaks called using MACS (version 1.4) on standard
settings. Our list of NF-κB targets was acquired by intersecting the known coding
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genes in Ensembl mouse build 73 with our NF-κB subunit (p65) peaks using
bedtools (intersect).
The replicate BT-549 siControl #3 was incorrectly sequenced and was therefore
removed from the analyses.
Reverse transcription quantitative PCR array (RT-qPCR). For RNA-Seq vali-
dation, a fast 48+ TaqMan-based qPCR array (4413257, Life Technologies) was
customized and used to profile Hs 578T cells upon siRNA-mediated PAK4
depletion. This array was later employed to profile Hs 578T cells upon transient
transfection of FLAG-RELB-wt versus FLAG-RELB-S151E.
The array consisted of a selection of 44 genes that were found DE upon PAK4
knockdown by RNA-Seq and that have been shown to play a role in senescence-
associated phenotypes plus four housekeeping genes. The following TaqMan gene
expression assays were used: 18s rRNA (Assay ID: Hs99999901_s1, housekeeping
gene), BID (Assay ID: Hs00609632_m1), BIRC3 (Assay ID: Hs00985031_g1),
BRAT1 (Assay ID: Hs00378008_m1), CCNG1 (Assay ID: Hs00171112_m1), CD82
(Assay ID: Hs01017982_m1), CDK1 (Assay ID: Hs00938777_m1), CDKN1C
(Assay ID: Hs00175938_m1), CDKN2D (Assay ID: Hs00176481_m1), CEBPB
(Assay ID: Hs00270923_s1), CSF1 (Assay ID: Hs00174164_m1), CYTL1 (Assay ID:
Hs01573280_m1), DSCC1 (Assay ID: Hs00225430_m1), E2F1 (Assay ID:
Hs00153451_m1), E2F2 (Assay ID: Hs00231667_m1), E2F3 (Assay ID:
Hs00605457_m1), E2F6 (Assay ID: Hs00242501_m1), FANCM (Assay ID:
Hs00326216_m1), GAPDH (Assay ID: Hs99999905_m1, housekeeping gene),
GUSB (Assay ID: Hs99999908_m1, housekeeping gene), HES1 (Assay ID:
Hs00172878_m1), HEY1 (Assay ID: Hs01114113_m1), HEY2 (Assay ID:
Hs00232622_m1), HPRT (Assay ID: Hs99999909_m1, housekeeping gene),
ICAM1 (Assay ID: Hs00164932_m1), IL8 (Assay ID: Hs00174103_m1), LIG1
(Assay ID: Hs01553527_m1), MAP2K6 (Assay ID: Hs00992389_m1), MCM10
(Assay ID: Hs00960349_m1), NFKB1 (Assay ID: Hs00765730_m1), NFKB2(Assay
ID: Hs01028901_g1), OSGIN1 (Assay ID: Hs00203539_m1), PAK4 (Assay ID:
Hs01100061_m1), PCNA (Assay ID: Hs00427214_g1), POLA1 (Assay ID:
Hs00415835_m1), PRKDC (Assay ID: Hs00179161_m1), RBL1(Assay ID:
Hs00765700_m1), RELB (Assay ID: Hs00232399_m1), S100A4 (Assay ID:
Hs00243202_m1), SNAI2 (Assay ID: Hs00950344_m1), SPP1 (Assay ID:
Hs00959010_m1), TIMP2 (Assay ID: Hs00234278_m1), TIPIN (Assay ID:
Hs00762756_s1), TNFRSF11B (Assay ID: Hs00900358_m1), TONSL (Assay ID:
Hs00273774_m1), TP53 (Assay ID: Hs01034249_m1), TRAF2 (Assay ID:
Hs00184192_m1), and TWIST1 (Assay ID: Hs01675818_s1).
Total RNA was isolated using the RNeasy Mini Kit (74104, Qiagen) as specified
by the manufacturer. RNA quality was assessed with Agilent 2100 Bioanalyzer
(Agilent Technologies) prior to the qPCR array run according to the
manufacturer’s instructions at the BEA core facility in Stockholm. RT-qPCR
reactions were carried out in biological triplicates.
Recombinant proteins and protein purification. GST-tagged human RELB (GST-
RELB) was commercially available (H00005971-P01, Tebu-bio). GST and GST-
tagged murine RELB-N, -C, and -RHD (GST-RELB-N, GST-RELB-C, and GST-
RELB-RHD)53 were purified with Glutathione Sepharose 4B (17–0756–01, GE
Healthcare) according to the manufacturer’s instructions. Briefly, plasmids were
transformed into BL21 Star (DE3) Escherichia coli (C601003, ThermoFisher) and
the bacteria were grown in Luria–Bertani broth plates and media in the presence of
ampicillin (A9518, Sigma). Protein expression was induced in early log phase
cultures with 0.1 mM IPTG (I5502, Sigma). After 4 h at 37 °C, cells were harvested
and lysed by sonication in ice-cold PBS containing cOmplete protease inhibitor
cocktail (1697498, Sigma). Triton X-100 (X100, Sigma) was added to a final con-
centration of 1% and GST-tagged proteins were purified with Glutathione
Sepharose 4B (17–0756–01, GE Healthcare) according to the manufacturer’s
instructions. Expression of GST-tagged hRELB aa 102–400 (GST-RHD) and
mutant GST-RHD-S151A was induced with 0.2 mM IPTG (I5502, Sigma) at 16 °C
overnight.
Recombinant His-tagged PAK4 was produced by expressing the His-PAK4
construct in BL21Star (DE3) Escherichia coli as described earlier51. Plasmid
expression was induced by 0.5 mM IPTG and the bacteria were grown for 4 h at
37 °C prior to lysis with 0.3 M NaCl, 50 mM Tris-HCl pH 8.0 and sonication on
ice. The protein was then purified on an HIS-Select HF Nickel Affinity Gel (H0537,
Sigma) in accordance with the manufacturer's protocol. Purified protein was
dialyzed against PBS and concentrated.
Generation of anti-PAK4 antibodies. For anti-PAK4 antibody production, a
PAK4 NH2-terminal sequence (aa 1–326) was amplified by PCR and cloned into
the PET15b vector (Novagen). His-tagged fusion protein was expressed in BL21
De3Lys strain of Esherichia coli, solubilized in 50 mM Tris-HCl pH 8.0 with 0.3 M
NaCl buffer and purified by absorption-elution on HIS-select HF Nickel affinity gel
(Sigma) followed by dialysis against PBS. This PAK4 fusion protein in its native
state has been used to generate anti-PAK4 6508. This fusion protein was fixed with
PFA prior to injection into rabbits to generate anti-PAK4 serum #73. The IgG
fraction from serum was purified on an affinity column consisting of the full-length
PAK4 protein (prepared as above) coupled to CNBr-activated Sepharose 4B
(Amersham), generating anti-PAK4 pabs 6508 and 73. Sera are available upon
request for noncommercial use.
In vitro kinase assays. In vitro radioactive kinase assays were performed where
purified His-tagged PAK4 was incubated with GST-tagged RELB proteins as
putative substrates. In brief, 2 μg of the indicated GST fusion proteins were
incubated with 2 μg of purified His-tagged PAK4 in PAK-kinase buffer (100 mM
HEPES pH7.5, 20 mM MgCl2, 4 mM MnCl2, and 0.4 mM DTT). Kinase reactions
were performed in the presence of 5 μCi [γ-32P]-ATP (NEG502A250UC, Perki-
nElmer) and 60 μM cold ATP (A3377, Sigma) at 30 °C for 30 min. The reactions
were stopped by boiling at 95 °C in 5× SDS loading buffer. Samples were resolved
by SDS-PAGE; the gels were fixed in 7% acetic acid and 20% methanol and stained
with Coomassie Blue dye (443283M, VWR). The radioactivity incorporated into
the substrate was visualized and quantified by autoradiography and Phosphor-
Imager analysis (Molecular Imager FX, Bio-Rad).
Mass spectrometric analysis. GST-RHD (GST-tagged hRELB aa 102–400) was
phosphorylated by His–PAK4 in vitro and analyzed by MS.
Gel lanes with proteins were excised manually from Coomassie-stained gels.
The lanes, cut in several pieces, were processed and digested by trypsin using a
robotic protein handling system (MassPREP, Waters). Proteins were reduced with
10 mM dithiothreitol (DTT, Sigma) in 100 mM ammonium bicarbonate and
incubated at 40 °C for 30 min 55 mM iodoacetamide (Sigma) in 100 mM
ammonium bicarbonate was added for alkylation at 40 °C for 20 min Then 0.3 μg
of sequencing grade modified trypsin (Promega) was added to each gel piece and
incubated for 4.5 h at 40 °C. Peptides were extracted with 30 μl of 5% formic acid/
2% acetonitrile, followed by extraction with 24 μl of 2.5% formic acid/50%
acetonitrile, cleaned with C18 StageTip and dried the peptide extracts using a
Speedvac before resuspending in 0.1% Formic Acid and 2% acetonitrile.
Chromatographic separation of peptides was achieved using 50 cm EASY-spray
C18 column connected to EASY-nLC 1000 system (ThermoFisher). Eluted at 300
nL/min flow rate for 60 min at a linear gradient from 2% to 26% ACN in 0.1%
formic acid. Orbitrap Fusion mass spectrometer (ThermoFisher) analyzed the
eluted peptides that were ionized with electrospray ionization. The survey MS
spectrum was acquired at the resolution of 120,000 in the range of m/z 350–1500.
MS/MS data were obtained with a higher-energy collisional dissociation (HCD)
and electron-transfer dissociation (ETD) for ions with charge z > 1 at a resolution
of 30,000.
The raw data files were converted to Mascot Generic Format (mgf) using in-
house written Raw2mgf program. Proteins were identified by searching mgf files w
against SwissProt database and with variable modifications, Deamidated (NQ),
Oxidation (M), Phospho (ST), Phospho (Y), using Mascot v 2.3.0 (MatrixScience)
database search engine.
Detection of phosphorylation sites within RELB. The RELB gene was searched
for in the Phosida38 and PhosphoSitePlus62 databases in accordance with the
suppliers’ guide. Literature was curated for additional residues. Residues previously
identified in murine RELB were converted to the corresponding human residue for
display.
Clinical data and gene expression profiling. The role of PAK4 gene expression in
clinical samples was explored on the previously published METABRIC data14.
Briefly, 1980 patients were included in this study that performed transcriptional
profiling (Illumina HT-12 v3 platform) of 1992 primary tumor specimen and
tumor adjacent normal tissue (144 samples) from biobanks in the UK and Canada.
All clinical-pathological characteristics, PAM50 subtypes, Integrative subtypes,
and survival outcome information were obtained from the original publication.
The normalized data were downloaded from the European genome-phenome
archive platform (https://www.ebi.ac.uk/ega/studies/EGAS00000000083, accessed
on Mars 2015). The 3 PAK4 annotated probes had Spearman correlation
coefficients 0.55, 0.03, and −0.03. The most varying probe that targets all PAK4
transcript variants (ILMN_1728887) was selected for further analysis. A gene
expression based proliferation module score was computed as previously
described35.
PAK4 gene expression was explored in the Oncomine cancer microarray
database and web-based data-mining platform (accessed in December 2016)63.
PAK4 mRNA levels were compared in breast carcinomas versus normal breast
tissues in the TCGA16 (n= 93 carcinomas versus n= 61 normal) and Zhao17 (n=
38 carcinomas versus n= 3 normal) datasets.
The somatic mutation and copy number segmentation data of the breast cancer
cell lines were downloaded from the CCLE data portal (www.portals.broadinstitute.
org/ccle)64. Prior knowledge about and recurrence of mutations were analyzed
using OncoKB65 (www.oncokb.org), Cancer Hotspots66,67 (www.cancerhotspots.
org), and 3D Hotspots68 (www.3dhotspots.org). Copy number data were post‐
processed by using the GISTIC2.069 module on GenePattern70 (www.genepattern.
broadinstitute.org) running default parameters. Copy number alteration and
clinical data of the TCGA breast cancer samples (n= 987) were downloaded
from Broad GDAC Firehose (https://ezid.cdlib.org/id/doi:10.7908/C11G0KM9)
(www.gdac.broadinstitute.org). Patients were stratified according to their PAK4
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copy‐number status (all other versus amplification) and further analyzed using the
Kaplan‐Meier method and compared by the logrank (Mantel‐Cox) test carried out
with SPSS Statistics software version 23 (IBM Corporation, Armonk, NY, USA).
Statistics. Group size was based on previous experience. No statistical method was
used to predetermine sample size. Unless otherwise noted, each experiment was
repeated three or more times. Data shown in column graphs represent mean ±
standard error of the mean (SEM) or mean ± standard deviation (SD), as indicated
in the figure legends, and individual data points are plotted. Statistical analysis was
performed with GraphPad Prism 6.0. Details of statistical testing can be found in
the figure legends and in the source data file. All datasets were tested for Gaussian
distribution using the Kolmogorov–Smirnov test.
Statistical analysis of the METABRIC clinical data is described in detail below.
The association between PAK4 and clinical-pathological characteristics was
assessed by Mann–Whitney tests (two groups) or Spearman correlation test
(continuous variable). OS and DSS endpoints were used to explore the prognostic
ability of PAK4. Deaths of an unknown cause were excluded in analyses of the DSS
endpoint. Some sensitivity analyses including deaths of an unknown cause as an
event of the DSS endpoint demonstrated consistency in the results. In all patients
as well as in the subgroup of untreated patients (not receiving any adjuvant
treatment), PAK4 association with both endpoints was investigated in univariable
and multivariable Cox models stratified by site (as suggested in the original
publication). The multivariable Cox models were adjusted by tumor size, lymph
node status, tumor grade, age at diagnosis, and PAM50 subtype. The univariable
prognostic role of PAK4 categorized according to quartiles was visualized by the
Kaplan–Meier method.
Association between PAK4 expression and modules that reflect biological
processes in breast cancer35,36, NF-κB signaling37, and NF-κB subunits in tumor
clinical samples was quantified by Spearman's rank correlation.
The analysis is exploratory. All statistical analyses were done with R statistical
software v3.1.0.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-Seq data reported here has been deposited in the NCBI Geo under ID code:
GSE112817. Exome-Seq data are available in SRA under the accession code
PRJNA545882. Remaining primary data of interest is provided in the source data file of
this paper.
Code availability
R code used in this study has been deposited on GitHub (https://github.com/
CostaNatCommun19/analysisPublicData).
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